You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

camrelizumab

Showing 376 - 388 of 388
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Perihilar Cholangiocarcinoma Trial in Guangzhou (PD-1antibody plus GEMOX)

Not yet recruiting
  • Perihilar Cholangiocarcinoma
  • PD-1antibody plus GEMOX
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Jul 31, 2022

TACE in Combination With ICIs for HCC: a Real-world Study

Recruiting
  • Hepatocellular Carcinoma
  • TACE+ICIs
  • TACE
  • Nanjing, China
    Gao-Jun Teng
Jul 22, 2021

Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III Trial in Shanghai (Neoadjuvant

Recruiting
  • Esophageal Squamous Cell Carcinoma Stage II
  • Esophageal Squamous Cell Carcinoma Stage III
  • Neoadjuvant Chemoradiotherapy
  • +2 more
  • Shanghai, China
    Shanghai Zhongshan Hospital
Jun 26, 2022

Nasopharyngeal Tumors Trial in Guangzhou (Tis-U-Sol)

Not yet recruiting
  • Nasopharyngeal Neoplasms
  • Guangzhou, Guangdong, China
    Affiliated Cancer Hospital & Institute of Guangzhou Medical Univ
Jun 3, 2021

Advanced/Metastatic Hepatocellular Carcinoma Trial (Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib)

Not yet recruiting
  • Advanced/Metastatic Hepatocellular Carcinoma
  • Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib
  • (no location specified)
Jan 20, 2021

Nasopharyngeal Carcinoma Trial in Guangzhou (GP combine with Tislelizumab neoadjuvant therapy+CCRT)

Recruiting
  • Nasopharyngeal Carcinoma
  • GP combine with Tislelizumab neoadjuvant therapy+CCRT
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Apr 15, 2021

Biliary Tract Cancer, Extrahepatic Cholangiocarcinoma, Gallbladder Cancer Trial in Guangzhou (drug, other, procedure, radiation)

Active, not recruiting
  • Biliary Tract Cancer
  • +2 more
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital of Sun Yat-sen University
Jun 20, 2020

ESCC Trial in Chongqing (TC/PD-1 inhibitor/anlotinib)

Not yet recruiting
  • ESCC
  • TC/PD-1 inhibitor/anlotinib
  • Chongqing, Chongqing, China
    Daping Hospital, Third Military Medical University
Jul 12, 2020

Nasopharyngeal Carcinoma Trial in Shanghai (Toripalimab, IMRT to the nasopharynx and neck, Gemcitabine and Cisplatin

Recruiting
  • Nasopharyngeal Carcinoma
  • Shanghai, China
    Xiaomin Ou
Jul 25, 2021

Locally Advanced Pancreatic Cancer Trial in Beijing (carleilizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound))

Not yet recruiting
  • Locally Advanced Pancreatic Cancer
  • carleilizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound)
  • Beijing, Beijing, China
  • +1 more
Jan 22, 2021

Progression-free Survival, Overall Survival, Clinical Benefit Rate Trial in Beijing (Apatinib, SHR-1210)

Completed
  • Progression-free Survival
  • +3 more
  • Beijing, China
  • +1 more
May 15, 2020

Nasopharyngeal Carcinoma Trial in China (PD-1 blocking antibody, Gemcitabine, Cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • PD-1 blocking antibody
  • +3 more
  • Fuzhou, Fujian Provinve, China
  • +5 more
Dec 5, 2020

Esophageal Squamous Cell Carcinoma Trial in Shanghai (Nivolumab, Cisplatin, Paclitaxel)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Shanghai, China
    180 Fenglin Road
Jun 12, 2022